---
document_datetime: 2023-09-21 17:04:37
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/rotateq-epar-all-authorised-presentations_en.pdf
document_name: rotateq-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.3242165
conversion_datetime: 2025-12-15 20:12:21.899281
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| EU Number       | Invented name   | Strength   | Pharmaceutical   | Route of   | Packaging   | Content   |   Package size |
|-----------------|-----------------|------------|------------------|------------|-------------|-----------|----------------|
| EU/1/06/348/001 | RotaTeq         | _*_        | Oral solution    | Oral use   | tube (LDPE) | 2 ml      |              1 |
| EU/1/06/348/002 | RotaTeq         | _*_        | Oral solution    | Oral use   | tube (LDPE) | 2 ml      |             10 |

## \\_*\\_One 2-ml dose contains:

| rotavirus serotype* G1    | not less than 2.2 x 10 6 IU 1, 2   |
|---------------------------|------------------------------------|
| rotavirus serotype* G2    | not less than 2.8 x 10 6 IU 1, 2   |
| rotavirus serotype* G3    | not less than 2.2 x 10 6 IU 1, 2   |
| rotavirus serotype* G4    | not less than 2.0 x 10 6 IU 1, 2   |
| rotavirus serotype* P1[8] | not less than 2.3 x 10 6 IU 1, 2   |

* human-bovine rotavirus reassortants (live), produced in Vero cells.

1 Infectious Units

2 As lower confidence limit (p = 0.95)